Results of an ophthalmologic screening programme for identification of cases with anderson-fabry disease

Ophthalmologica

Volumn 218, Issue 3, 2004, Pages 207-209

  Hauser, Anna Christine ^a   Lorenz, Matthias ^a   Voigtländer, Till ^b   Födinger, Manuela ^a   Sunder Plassmann, Gere ^a  

^a UNIVERSITY OF VIENNA   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anderson fabry disease; Cornea verticillata; Ophthalmologic screening programme; Tortuositas vasorum

Indexed keywords

ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; EYE MALFORMATION; FABRY DISEASE; FEMALE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; LABORATORY DIAGNOSIS; MALE; MASS SCREENING; MEDICAL EXAMINATION; QUESTIONNAIRE;

AUSTRIA; FABRY DISEASE; FEMALE; HUMANS; INCIDENCE; INTERNSHIP AND RESIDENCY; MALE; MASS SCREENING; OPHTHALMOLOGY; PHYSICIANS; QUESTIONNAIRES;

EID: 2342580804     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076846     Document Type: Article

References (17)

1. Schiffmann R, Kopp JB, Austin HA 3rd, et al: Enzyme replacement therapy in Fabry disease: A randomized controlled trial. JAMA 2001;285:2743-2749.
2. Kolodny EH, Pastores GM: Anderson-Fabry disease: Extrarenal, neurologic manifestations. J Am Soc Nephrol 2002;13(suppl 2):S150-S153.
3. Pastores GM, Thadhani R: Enzyme-replacement therapy for Anderson-Fabry disease. Lancet 2001;358:601-603.
4. MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001;38:750-760.
5. MacDermot KD, Holmes A, Miners AH: Anderson-Fabry disease: Clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001;38:769-775.
6. Kampmann Ch, Baehner F, Ries M, et al: Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol 2002;13(suppl 2):S147-S149.
7. Franceschetti AT: Fabry disease: Ocular manifestations. Birth Defects Original Article Ser 1976;12:195-208.
8. Sher NA, Letson RD, Desnick RJ: The ocular manifestations in Fabry disease. Arch Ophthalmol 1979;97:671-676.
9. Desnick RJ, Ioannou YA, Eng CM: α-Galactosidase A deficiency: Fabry disease; in Scriver CR, Beaudet AL, Sly WS, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease, ed 8. New York, McGraw Hill, 2001, vol 3, pp 3733-3774.
10. Peters FPJ, Vermeulen A, Kho TL: Anderson-Fabry's disease: Galactosidase deficiency. Lancet 2001;357:138-140.
11. Levy M, Feingold J: Estimating prevalence in single-gene kidney diseases progressing to renal failure. Kidney Int 2000;58:925-943.
12. Meikle PJ, Hopwood JJ, Clague AE, et al: Prevalence of lysosomal storage disorders. JAMA 1999;281:249-254.
13. Morgan SH, Crawfurd MA: Anderson-Fabry disease. BMJ 1988;297:872-873.
14. Nakao S, Takenaka T, Maeda M, et al: An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-293.
15. Beer G, Reinecke P, Gabbert HE, et al: Fabry disease in patients with hypertrophic cardiomyopathy. Z Kardiol 2002;91:992-1002.
16. Brady RO: Ophthalmologic aspects of lipid storage diseases. Ophthalmology 1978;85:1007-1013.
17. Lorenz M, Hauser AC, Püspök-Schwarz M, et al: Anderson-Fabry disease in Austria. Wien Klin Wochenschr 2003;115:235-240.